Ambagon Therapeutics
Ambagon Therapeutics develops a new class of medicines focused on 14-3-3 molecular glues to target intrinsically disordered proteins. The company utilizes a platform designed to address a wide range of proteins previously considered undruggable. Their research aims to expand the druggable proteome to create therapeutics for challenging disease targets.
Visit websiteEindhoven, Netherlands
Biotechnology
Biopharma
Healthcare
Funding summary
- Total raised
- €75.2M
- Funding rounds
- 1
Investors in Ambagon Therapeutics
Investors on record for Ambagon Therapeutics. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Ambagon Therapeutics?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors